• 1
    Willeberg P, Priester WA. Epidemiological aspects of clinical hyperadrenocorticism in dogs (canine Cushing's syndrome). J Am Anim Hosp Assoc 1982;18:717724.
  • 2
    Galac S, Reusch CE, Kooistra HS, Rijnberk A. Adrenals. In: Second, revised and extended edition, ed. Clinical Endocrinology of Dogs and Cats. Hannover: Schlütersche; 2010:93154.
  • 3
    Feldman EC, Nelson RW. Comparative aspects of Cushing's syndrome in dogs and cats. Endocrinol Metab Clin North Am 1994;23:671691.
  • 4
    Kooistra HS, Galac S, Buijtels JJ, Meij BP. Endocrine diseases in animals. Horm Res 2009;71(Suppl 1):144147.
  • 5
    Gallo-Payet N, Payet MD. Mechanism of action of ACTH: Beyond cAMP. Microsc Res Tech 2003;61:275287.
  • 6
    Latronico AC, Reincke M, Mendonca BB, et al. No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms. J Clin Endocrinol Metab 1995;80:875877.
  • 7
    Light K, Jenkins PJ, Weber A, et al. Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia? Life Sci 1995;56:15231527.
  • 8
    Beuschlein F, Fassnacht M, Klink A, et al. ACTH-receptor expression, regulation and role in adrenocortial tumor formation. Eur J Endocrinol 2001;144:199206.
  • 9
    Kobayashi H, Usui T, Fukata J, et al. Mutation analysis of Gsalpha, adrenocorticotropin aeceptor and p53 genes in Japanese patients with adrenocortical neoplasms: Including a case of Gsalpha mutation. Endocr J 2000;47:461466.
  • 10
    Dall'Asta C, Ballare E, Mantovani G, et al. Assessing the presence of abnormal regulation of cortisol secretion by membrane hormone receptors: In vivo and in vitro studies in patients with functioning and non-functioning adrenal adenoma. Horm Metab Res 2004;36:578583.
  • 11
    Lumbroso S, Paris F, Sultan C. European Collaborative Study. Activating Gsalpha mutations: Analysis of 113 patients with signs of McCune-Albright syndrome – a European collaborative study. J Clin Endocrinol Metab 2004;89:21072113.
  • 12
    Peeters ME, Timmermans-Sprang EP, Mol JA. Feline thyroid adenomas are in part associated with mutations in the G(s Alpha) gene and not with polymorphisms found in the thyrotropin receptor. Thyroid 2002;12:571575.
  • 13
    Hayward BE, Barlier A, Korbonits M, et al. Imprinting of the G(s)Alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001;107:R31R36.
  • 14
    Nishihara E, Amino N, Maekawa K, et al. Prevalence of TSH receptor and Gsalpha mutations in 45 autonomously functioning thyroid nodules in Japan. Endocr J 2009;56:791798.
  • 15
    Mantovani G, Bondioni S, Lania AG, et al. Parental origin of Gsalpha mutations in the McCune-Albright syndrome and in isolated endocrine tumors. J Clin Endocrinol Metab 2004;89:30073009.
  • 16
    Libe R, Mantovani G, Bondioni S, et al. Mutational analysis of PRKAR1A and Gs(Alpha) in sporadic adrenocortical tumors. Exp Clin Endocrinol Diabetes 2005;113:248251.
  • 17
    Robinson-White A, Meoli E, Stergiopoulos S, et al. PRKAR1A mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex. J Clin Endocrinol Metab 2006;91:23802388.
  • 18
    Bertherat J, Bertagna X. Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab 2009;23:261271.
  • 19
    Rothenbuhler A, Stratakis CA. Clinical and molecular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab 2010;24:389399.
  • 20
    Bertherat J, Groussin L, Sandrini F, et al. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 2003;63:53085319.
  • 21
    Adissu HA, Hayes G, Wood GA, Caswell JL. Cardiac myxosarcoma with adrenal adenoma and pituitary hyperplasia resembling Carney complex in a dog. Vet Pathol 2010;47:354357.
  • 22
    Galac S, Kool MM, Naan EC, et al. Expression of the ACTH receptor, steroidogenic acute regulatory protein, and steroidogenic enzymes in canine cortisol-secreting adrenocortical tumors. Domest Anim Endocrinol 2010;39:259267.
  • 23
    Labelle P, Kyles AE, Farver TB, De Cock HE. Indicators of malignancy of canine adrenocortical tumors: Histopathology and proliferation index. Vet Pathol 2004;41:490497.
  • 24
    Freda PU, Chung WK, Matsuoka N, et al. Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: Correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary 2007;10:275282.
  • 25
    Palos-Paz F, Perez-Guerra O, Cameselle-Teijeiro J, et al. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. Eur J Endocrinol 2008;159:623631.
  • 26
    Nault JC, Fabre M, Couchy G, et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol 2012;56:184191.
  • 27
    Almeida MQ, Azevedo MF, Xekouki P, et al. Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations. J Clin Endocrinol Metab 2012;97:E687E693.
  • 28
    Bray P, Carter A, Simons C, et al. Human cDNA clones for four species of G Alpha s signal transduction protein. Proc Natl Acad Sci USA 1986;83:88938897.
  • 29
    Mumby SM, Kahn RA, Manning DR, Gilman AG. Antisera of designed specificity for subunits of guanine nucleotide-binding regulatory proteins. Proc Natl Acad Sci USA 1986;83:265269.
  • 30
    Walseth TF, Zhang HJ, Olson LK, et al. Increase in Gs and cyclic AMP generation in HIT cells. Evidence that the 45-kDa alpha-subunit of Gs has greater functional activity than the 52-kDa alpha-subunit. J Biol Chem 1989;264:2110621111.
  • 31
    Graziano MP, Freissmuth M, Gilman AG. Expression of Gs alpha in Escherichia coli. Purification and properties of two forms of the protein. J Biol Chem 1989;264:409418.
  • 32
    Seifert R, Wenzel-Seifert K, Lee TW, et al. Different effects of Gsalpha splice variants on beta2-adrenoreceptor-mediated signaling. The beta2-adrenoreceptor coupled to the long splice variant of Gsalpha has properties of a constitutively active receptor. J Biol Chem 1998;273:51095116.
  • 33
    Bastepe M. The GNAS Locus: Quintessential complex gene encoding Gsalpha, XLalphas, and other imprinted transcripts. Curr Genomics 2007;8:398414.
  • 34
    Almeida MQ, Stratakis CA. How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues? Mol Cell Endocrinol 2011;336:162168.
  • 35
    Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990;249:655659.
  • 36
    Kotoula V, Sozopoulos E, Litsiou H, et al. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer 2009;16:565572.
  • 37
    Waldmann J, Patsalis N, Fendrich V, et al. Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbecks Arch Surg 2012;397:209216.
  • 38
    Inoue J, Gohda J, Akiyama T, Semba K. NF-kappaB Activation in development and progression of cancer. Cancer Sci 2007;98:268274.
  • 39
    Golubovskaya VM, Cance W. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front Biosci 2010;15:901912.
  • 40
    Sahut-Barnola I, de Joussineau C, Val P, et al. Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. PLoS Genet 2010;6:e1000980.
  • 41
    Griffin KJ, Kirschner LS, Matyakhina L, et al. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: Comparison with Carney complex and other PRKAR1A induced lesions. J Med Genet 2004;41:923931.
  • 42
    Kirschner LS, Kusewitt DF, Matyakhina L, et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res 2005;65:45064514.
  • 43
    Gaujoux S, Tissier F, Groussin L, et al. Wnt/beta-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 2008;93:41354140.